Rosette-Forming Glioneuronal Tumor of the Fourth Ventricle: A Case of Relapse Treated with Proton Beam Therapy.
Rosette-forming glioneuronal tumors
pediatric brain tumor
proton beam therapy
relapse
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
19 May 2021
19 May 2021
Historique:
received:
31
03
2021
revised:
07
05
2021
accepted:
07
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Rosette-forming glioneuronal tumors (RGNTs) are rare, grade I, central nervous system (CNS) tumors typically localized to the fourth ventricle. We describe a 9-year-old girl with dizziness and occipital headache. A magnetic resonance imaging (MRI) revealed a large hypodense posterior fossa mass lesion in relation to the vermis, with cystic component. Surgical resection of the tumor was performed. A RGNT diagnosis was made at the histopathological examination. During follow-up, the patient experienced a first relapse, which was again surgically removed. Eight months after, MRI documented a second recurrence at the local level. She was a candidate for the proton beam therapy (PBT) program. Three years after the end of PBT, the patient had no evidence of disease recurrence. This report underlines that, although RGNTs are commonly associated with an indolent course, they may have the potential for aggressive behavior, suggesting the need for treatment in addition to surgery. Controversy exists in the literature regarding effective management of RGNTs. Chemotherapy and radiation are used as adjuvant therapy, but their efficacy management has not been adequately described in the literature. This is the first case report published in which PBT was proposed for adjuvant therapy in place of chemotherapy in RGNT relapse.
Identifiants
pubmed: 34069450
pii: diagnostics11050903
doi: 10.3390/diagnostics11050903
pmc: PMC8159123
pii:
doi:
Types de publication
Case Reports
Langues
eng
Références
J Neurol Sci. 2017 Feb 15;373:280-284
pubmed: 28131206
Brain Tumor Pathol. 2014 Jan;31(1):17-22
pubmed: 23329202
J Clin Oncol. 2003 Sep 1;21(17):3255-61
pubmed: 12947060
J Natl Cancer Inst. 2013 Jun 19;105(12):899-907
pubmed: 23584394
Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001057
pubmed: 27626068
Acta Neuropathol. 2012 Feb;123(2):285-7
pubmed: 21997360
Brain Pathol. 2007 Jul;17(3):308-13
pubmed: 17598823
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Am J Surg Pathol. 2002 May;26(5):582-91
pubmed: 11979088
Neurol India. 2011 Mar-Apr;59(2):276-80
pubmed: 21483133
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):133-138
pubmed: 26700707
NMC Case Rep J. 2015 Mar 09;2(2):65-67
pubmed: 28663967
J Neurooncol. 2012 Oct;110(1):21-5
pubmed: 22814862
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
Adv Anat Pathol. 2009 Jan;16(1):33-9
pubmed: 19098465
Br J Neurosurg. 2012 Oct;26(5):668-73
pubmed: 22512825
PLoS One. 2014 Jul 03;9(7):e101211
pubmed: 24991807
World Neurosurg. 2017 Nov;107:1045.e9-1045.e16
pubmed: 28826709
Childs Nerv Syst. 2013 May;29(5):839-47
pubmed: 23239254
Neurochirurgie. 2016 Feb;62(1):60-3
pubmed: 26705911
Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1531-1547
pubmed: 29200109
J Clin Oncol. 2019 Dec 10;37(35):3335-3339
pubmed: 31498029
PLoS One. 2015 Sep 15;10(9):e0137690
pubmed: 26371886
Acta Neuropathol. 2019 Sep;138(3):497-504
pubmed: 31250151
J Clin Neurosci. 2012 Aug;19(8):1180-1
pubmed: 22613490
Radiother Oncol. 2015 Aug;116(2):301-8
pubmed: 26243681
Neuropathol Appl Neurobiol. 2006 Apr;32(2):217-20
pubmed: 16599951
Neurooncol Adv. 2020 Sep 09;2(1):vdaa116
pubmed: 33134925
Pediatr Blood Cancer. 2008 Jul;51(1):110-7
pubmed: 18306274
Clin Neuropathol. 2011 Nov-Dec;30(6):297-300
pubmed: 22011734
Neurol Med Chir (Tokyo). 2010;50(3):224-8
pubmed: 20339273
Pathol Int. 2019 Jun;69(6):372-377
pubmed: 31218776
Eur J Paediatr Neurol. 2010 Jul;14(4):298-303
pubmed: 20110182
World Neurosurg X. 2019 Jan 05;2:100006
pubmed: 31218281